<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
		<Article>
		<Journal>
			<PublisherName>OICC PRESS</PublisherName>
			<JournalTitle>Effects of PDCA cycle management on patients with acute myelocytic leukemia receiving decitabine combined with low dose idarubicin and cytarabine</JournalTitle>
			<Issn></Issn>
			<Volume>Volume 13 (2022) IJIC</Volume>
			<Issue>Issue 1, March 2022</Issue>
			<PubDate PubStatus="epublish">
                <Year>2023</Year>
                <Month>10</Month>
                <Day>03</Day>
			</PubDate>
		</Journal>
		<ArticleTitle>Effects of PDCA cycle management on patients with acute myelocytic leukemia receiving decitabine combined with low dose idarubicin and cytarabine</ArticleTitle>
		<VernacularTitle></VernacularTitle>
		<FirstPage></FirstPage>
		<LastPage></LastPage>
		<ELocationID EIdType="doi">10.47176/IJIC.13.1.1</ELocationID>
		<Language>EN</Language>
		<AuthorList>
            			<Author>
                				<FirstName>Bingling</FirstName>
				<LastName>Yin</LastName>
				<Affiliation>Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, 215000, Jiangsu, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Lei</FirstName>
				<LastName>Geng</LastName>
				<Affiliation>Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, 215000, Jiangsu, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            		</AuthorList>
		<PublicationType>Journal Article</PublicationType>
		<History>
			<PubDate PubStatus="received">
				<Year>2023</Year>
				<Month>10</Month>
				<Day>03</Day>
			</PubDate>
		</History>
		<Abstract>Acute myeloid leukemia (AML) is a hematologic neoplasm that occurs in adults, especially in the elderly. This study was performed to investigate the impact of a plan, do, check, act (PDCA)-based care management model on the clinical outcomes and quality of life of patients with AML receiving the decitabine (DCA) regimen in combination with low dose idarubicin + cytarabine (IA). Eighty-four patients with AML were enrolled in this study. Among them, 42 patients in the control group adopted DCA co-IA regiment and routine nursing, the other 42 cases in the observation group underwent the DCA co-IA regiment and PDCA nursing management. The immune function, hematopoietic function, clinical efficacy, quality of life, prognosis, and occurrence of adverse reactions were observed and compared between the two groups. After care, the observation group had higher CD4+ (P&lt;0.0001), CD4+/CD8+ (P=0.0022), HGB (P&lt;0.0001) and PLT (P&lt;0.0001) level, clinical treatment efficiency (P=0.0189), and nursing satisfaction (P=0.0066) in relation to the control group. However, the CD8+ (P&lt;0.0001), WBC (P&lt;0.0001), incidence of adverse reactions (P=0.0189, P=0.0347 and P=0.0206), SAS score (P&lt;0.001), SDS score (P&lt;0.001), and QLI score (P&lt;0.01) were lower in the observation group than those in the control group. In summary, the implementation of PDCA nursing management for AML patients undergoing DCA + IA chemotherapy treatment can improve patients’ immune function, clinical efficacy, quality of life and psychological status, reduce the occurrence of complications, and improve nursing satisfaction, which has clinical promotion value.</Abstract>
		<ObjectList>
            		</ObjectList>
	</Article>
		<Article>
		<Journal>
			<PublisherName>OICC PRESS</PublisherName>
			<JournalTitle>Evaluation of the efficacy and safety of FOLFIRINOX or albumin-bound paclitaxel in combination with S-1 in patients with pancreatic cancer</JournalTitle>
			<Issn></Issn>
			<Volume>Volume 13 (2022) IJIC</Volume>
			<Issue>Issue 1, March 2022</Issue>
			<PubDate PubStatus="epublish">
                <Year>2023</Year>
                <Month>10</Month>
                <Day>03</Day>
			</PubDate>
		</Journal>
		<ArticleTitle>Evaluation of the efficacy and safety of FOLFIRINOX or albumin-bound paclitaxel in combination with S-1 in patients with pancreatic cancer</ArticleTitle>
		<VernacularTitle></VernacularTitle>
		<FirstPage></FirstPage>
		<LastPage></LastPage>
		<ELocationID EIdType="doi">10.47176/IJIC.13.1.2</ELocationID>
		<Language>EN</Language>
		<AuthorList>
            			<Author>
                				<FirstName>Luan</FirstName>
				<LastName>Li</LastName>
				<Affiliation>Department of Medical Oncology, Jiangsu Cancer Hospital &amp; Jiangsu Institute of Cancer Research &amp; The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Yuxu</FirstName>
				<LastName>Feng</LastName>
				<Affiliation>Department of Orthopaedics, Pukou Central Hospital, PuKou Branch Hospital of Jiangsu Province Hospital, Nanjing, Jiangsu, People&rsquo;s Republic of China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Chenchen</FirstName>
				<LastName>Li</LastName>
				<Affiliation>Department of Medical Oncology, Jiangsu Cancer Hospital &amp; Jiangsu Institute of Cancer Research &amp; The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Siwen</FirstName>
				<LastName>Liu</LastName>
				<Affiliation>Department of Medical Oncology, Jiangsu Cancer Hospital &amp; Jiangsu Institute of Cancer Research &amp; The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Fei</FirstName>
				<LastName>Yan</LastName>
				<Affiliation>Department of Medical Oncology, Jiangsu Cancer Hospital &amp; Jiangsu Institute of Cancer Research &amp; The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Jingni</FirstName>
				<LastName>Zhu</LastName>
				<Affiliation>Department of Medical Oncology, Jiangsu Cancer Hospital &amp; Jiangsu Institute of Cancer Research &amp; The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Xiaoyou</FirstName>
				<LastName>Li</LastName>
				<Affiliation>Department of Medical Oncology, Jiangsu Cancer Hospital &amp;amp; Jiangsu Institute of Cancer Research &amp;amp; The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Sheng</FirstName>
				<LastName>Li</LastName>
				<Affiliation>Department of Medical Oncology, Jiangsu Cancer Hospital &amp; Jiangsu Institute of Cancer Research &amp; The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            		</AuthorList>
		<PublicationType>Journal Article</PublicationType>
		<History>
			<PubDate PubStatus="received">
				<Year>2023</Year>
				<Month>10</Month>
				<Day>03</Day>
			</PubDate>
		</History>
		<Abstract>To investigate the clinical efficacy and safety of FOLFIRINOX or albumin-bound paclitaxel (Abraxane) combined with S-1 after radical pancreatic cancer surgery.
A total of 133 patients who underwent adjuvant chemotherapy with the FOLFIRINOX (60 cases) or Abraxane combined with S-1 (73 cases) after radical resection pancreatic cancer were screened. According to the follow-up data, recurrence and metastasis, chemotherapy adverse reactions (nausea, vomiting, loss of appetite, leukopenia, thrombocytopenia, anemia, neurotoxicity, diarrhea), survival rate (OS), progression-free survival (PFS) and other indicators were collected to evaluate the efficacy and safety of the two chemotherapy regimens.
There was significant difference of metastatic tumor site between both groups (P&lt;0.001). The cases of DCR in the Abraxane + S-1 group were higher compared to the FOLFIRINOX group (P&lt;0.001). The occurrence of adverse events was significantly lower in Abraxane + S-1 group during I-II AE compared with the FOLFIRINOX group. However, there was no significant difference in the AE during III-IV between two groups (P&gt;0.05). The OS (HR=1.872, P=0.005) and PFS (HR=1.931, P=0.003) in Abraxane + S-1 group were significantly higher than those in the FOLFIRINOX group.
Adjuvant chemotherapy with Abraxane combined with S-1 regimen in patients with pancreatic cancer resection prolonged OS and PFS, improved DCR, with the overall adverse reactions safe and manageable compared with the FOLFIRINOX regimen.</Abstract>
		<ObjectList>
            		</ObjectList>
	</Article>
		<Article>
		<Journal>
			<PublisherName>OICC PRESS</PublisherName>
			<JournalTitle>Clinical efficacy and safety of inhibitors of programmed cell death protein 1 and its ligand in postoperative chemotherapy for advanced colorectal cancer</JournalTitle>
			<Issn></Issn>
			<Volume>Volume 13 (2022) IJIC</Volume>
			<Issue>Issue 1, March 2022</Issue>
			<PubDate PubStatus="epublish">
                <Year>2023</Year>
                <Month>10</Month>
                <Day>03</Day>
			</PubDate>
		</Journal>
		<ArticleTitle>Clinical efficacy and safety of inhibitors of programmed cell death protein 1 and its ligand in postoperative chemotherapy for advanced colorectal cancer</ArticleTitle>
		<VernacularTitle></VernacularTitle>
		<FirstPage></FirstPage>
		<LastPage></LastPage>
		<ELocationID EIdType="doi">10.47176/IJIC.13.1.3</ELocationID>
		<Language>EN</Language>
		<AuthorList>
            			<Author>
                				<FirstName>Xin</FirstName>
				<LastName>Shi</LastName>
				<Affiliation>Department of Oncology, The Fourth People&amp;amp;amp;#039;s Hospital of Jinan, Jinan 250031, Shandong, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Hongli</FirstName>
				<LastName>Gao</LastName>
				<Affiliation>Department of Oncology, The Fourth People&#039;s Hospital of Jinan, Jinan 250031, Shandong, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Qian</FirstName>
				<LastName>Zhao</LastName>
				<Affiliation>Department of Internal Medicine, The Fourth People&#039;s Hospital of Jinan, Jinan 250031, Shandong, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Mengqi</FirstName>
				<LastName>Zhuang</LastName>
				<Affiliation>Department of Oncology, The Fourth People&#039;s Hospital of Jinan, Jinan 250031, Shandong, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            		</AuthorList>
		<PublicationType>Journal Article</PublicationType>
		<History>
			<PubDate PubStatus="received">
				<Year>2023</Year>
				<Month>10</Month>
				<Day>03</Day>
			</PubDate>
		</History>
		<Abstract>This research aimed to investigate the safety and efficacy of inhibitors of programmed cell death 1 and its ligand in the postoperative chemotherapy for advanced colorectal cancer. Patients with advanced colorectal cancer treated in our hospital from June 2019 to June 2021 were included (23 patients receiving Apatinib served as the control group and 28 patients receiving programmed cell death protein 1 inhibitor served as the experiment group). The safety and clinical efficacy of these two treatments were analyzed. The experiment group showed 7.1% of objective remission rate and 89.3% of disease control rate while the Apatinib group showed 8.7% of objective remission rate and 56.5% of disease control rate. The experiment group also showed higher progression-free survival (6.4 months) than Apatinib group (3.9 months) (P = 0.0209). Patients with no V-Ki-ras2 Kirsten ratsarcoma viral oncogene homolog wild-type, liver metastases and left-sided colon tumors could benefit from the experiment group. No significant difference was observed in adverse events between the 2 groups, and 8 patients (15.7%) in total had treatment-related grade 3 adverse event. To sum up, inhibitor of programmed cell death protein 1 and its ligand is efficacious for advanced colorectal cancer, with well safety and tolerance.</Abstract>
		<ObjectList>
            		</ObjectList>
	</Article>
		<Article>
		<Journal>
			<PublisherName>OICC PRESS</PublisherName>
			<JournalTitle>Serum miR-589-5p is related to biochemical recurrence after radical prostatectomy in prostate cancer patients</JournalTitle>
			<Issn></Issn>
			<Volume>Volume 13 (2022) IJIC</Volume>
			<Issue>Issue 1, March 2022</Issue>
			<PubDate PubStatus="epublish">
                <Year>2023</Year>
                <Month>10</Month>
                <Day>03</Day>
			</PubDate>
		</Journal>
		<ArticleTitle>Serum miR-589-5p is related to biochemical recurrence after radical prostatectomy in prostate cancer patients</ArticleTitle>
		<VernacularTitle></VernacularTitle>
		<FirstPage></FirstPage>
		<LastPage></LastPage>
		<ELocationID EIdType="doi">10.47176/IJIC.13.1.4</ELocationID>
		<Language>EN</Language>
		<AuthorList>
            			<Author>
                				<FirstName>Kaiqiang</FirstName>
				<LastName>Chen</LastName>
				<Affiliation>Department of Urology, Beilun People&rsquo;s Hosptial, Ningbo City, Zhejiang Province, 315800, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Jun</FirstName>
				<LastName>Zhou</LastName>
				<Affiliation>Department of Urology, Beilun People&rsquo;s Hosptial, Ningbo City, Zhejiang Province, 315800, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Yuri</FirstName>
				<LastName>Kao</LastName>
				<Affiliation>Department of Urology, Beilun People&rsquo;s Hosptial, Ningbo City, Zhejiang Province, 315800, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Qianhao</FirstName>
				<LastName>Zhu</LastName>
				<Affiliation>Department of Urology, Beilun People&rsquo;s Hosptial, Ningbo City, Zhejiang Province, 315800, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Yaowu</FirstName>
				<LastName>Su</LastName>
				<Affiliation>Department of Urology, Beilun People&rsquo;s Hosptial, Ningbo City, Zhejiang Province, 315800, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Weihua</FirstName>
				<LastName>Liu</LastName>
				<Affiliation>Department of Urology, Beilun People&amp;rsquo;s Hosptial, Ningbo City, Zhejiang Province, 315800, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            		</AuthorList>
		<PublicationType>Journal Article</PublicationType>
		<History>
			<PubDate PubStatus="received">
				<Year>2023</Year>
				<Month>10</Month>
				<Day>03</Day>
			</PubDate>
		</History>
		<Abstract>miRNAs manifested aberrantly suggest an association with prostate cancer (PCa) progression, such as biochemical recurrence (BCR). Therefore, we explored the correlation between serum miR-589-5p and postoperative BCR in PCa patients. Sixty PCa patients who underwent radical prostatectomy were included, and another 60 matched healthy male volunteers served as the normal control. Serum miR-589-5p was detected by RT-qPCR, and then its correlation with clinicopathological features of PCa patients was analyzed. Our results showed that serum miR-589-5p in PCa patients was decreased compared with normal control, and was associated with invasive clinicopathologic features, including high preoperative PSA, late pathological staging, poor Gleason score, lymph node metastasis, and BCR. In addition, reduced miR-589-5p was linked with shorter BCR-free survival and had prognostic application in PCa patients’ BCR-free survival. Our results indicated that miR-589-5p is suppressed in PCa patients with postoperative BCR, which has a clinical application to be a biomarker.</Abstract>
		<ObjectList>
            		</ObjectList>
	</Article>
		<Article>
		<Journal>
			<PublisherName>OICC PRESS</PublisherName>
			<JournalTitle>Icariin improves atherosclerosis pathological environment by improving the balance of brown/white adipose tissue in an obesity mouse model</JournalTitle>
			<Issn></Issn>
			<Volume>Volume 13 (2022) IJIC</Volume>
			<Issue>Issue 1, March 2022</Issue>
			<PubDate PubStatus="epublish">
                <Year>2023</Year>
                <Month>10</Month>
                <Day>03</Day>
			</PubDate>
		</Journal>
		<ArticleTitle>Icariin improves atherosclerosis pathological environment by improving the balance of brown/white adipose tissue in an obesity mouse model</ArticleTitle>
		<VernacularTitle></VernacularTitle>
		<FirstPage></FirstPage>
		<LastPage></LastPage>
		<ELocationID EIdType="doi">10.47176/IJIC.13.1.5</ELocationID>
		<Language>EN</Language>
		<AuthorList>
            			<Author>
                				<FirstName>Rong</FirstName>
				<LastName>Shen</LastName>
				<Affiliation>Department of Geriatrics, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Xiangfeng</FirstName>
				<LastName>Xu</LastName>
				<Affiliation>Department of Rheumatology and Immunology, Zhoushan Hospital of Zhejiang Province, Zhoushan 316021, Zhejiang, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Sitong</FirstName>
				<LastName>Liu</LastName>
				<Affiliation>Department of Geriatrics, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Zhaozheng</FirstName>
				<LastName>Wang</LastName>
				<Affiliation>Department of Geriatrics, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Kai</FirstName>
				<LastName>Jiang</LastName>
				<Affiliation>Department of Geriatrics, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Juan</FirstName>
				<LastName>Gu</LastName>
				<Affiliation>Department of Geriatrics, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Li</FirstName>
				<LastName>Fang</LastName>
				<Affiliation>Department of Rheumatology and Immunology, Zhoushan Hospital of Zhejiang Province, Zhoushan 316021, Zhejiang, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            		</AuthorList>
		<PublicationType>Journal Article</PublicationType>
		<History>
			<PubDate PubStatus="received">
				<Year>2023</Year>
				<Month>10</Month>
				<Day>03</Day>
			</PubDate>
		</History>
		<Abstract>This study aimed to elucidate the effect and mechanism of Icariin (ICA) on brown adipose tissue (BAT) and to explore its influence on AS pathological environment in ApoE-/- mice.
The primary brown adipocytes were isolated from C57BL/6J mice and treated with ICA in different dosages. ApoE-/- mice were divided to 3 groups: the ordinary diet group, the high fat diet group, and the high fat diet with ICA treatment group. Cell morphology was observed by Oil Red O staining. Levels of UCP-1, BMP7, PRDM16, and PGC-1α were detected by RT-qPCR and western blotting. Mice body weight, BAT weight, and ratio of BAT/WAT weight were calculated. The levels of adipocytokines in serum were estimated. BMP7 expression in BAT and resistin expression in aorta were tested by immunohistochemical staining.
ICA promoted adipogenic differentiation and low dosage of ICA increased the expression of UCP-1, PRDM16, BMP7, and PGC-1α in brown adipocyte. ICA administration decreased body weight and serum triglyceride (TG) of AS mice, while serum adiponectin was increased. Meanwhile, ICA raised BAT weight, BAT/WAT ratio and increased BMP7 expression in BAT. ICA treatment group also showed higher UCP-1 level in both BAT and WAT, higher PRDM16 level in BAT and lower resistin level in WAT. In aortic wall of AS mice, resistin was decreased by ICA.
ICA may increase brown adipocyte differentiation by affecting BMP7 regulatory pathway. Moreover, it may motivate browning of WAT and improve the BAT/WAT balance to alleviate AS pathological environment of ApoE-/- mice.</Abstract>
		<ObjectList>
            		</ObjectList>
	</Article>
		<Article>
		<Journal>
			<PublisherName>OICC PRESS</PublisherName>
			<JournalTitle>Effect of whole-process health education based on self-management theory on self-efficacy and quality of life in patients with lung cancer</JournalTitle>
			<Issn></Issn>
			<Volume>Volume 13 (2022) IJIC</Volume>
			<Issue>Issue 1, March 2022</Issue>
			<PubDate PubStatus="epublish">
                <Year>2023</Year>
                <Month>10</Month>
                <Day>03</Day>
			</PubDate>
		</Journal>
		<ArticleTitle>Effect of whole-process health education based on self-management theory on self-efficacy and quality of life in patients with lung cancer</ArticleTitle>
		<VernacularTitle></VernacularTitle>
		<FirstPage></FirstPage>
		<LastPage></LastPage>
		<ELocationID EIdType="doi">10.47176/IJIC.13.1.6</ELocationID>
		<Language>EN</Language>
		<AuthorList>
            			<Author>
                				<FirstName>Tiantian</FirstName>
				<LastName>Yuan</LastName>
				<Affiliation>Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng Third People&#039;s Hospital, Yancheng, Jiangsu 224000, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Cuigan</FirstName>
				<LastName>Wu</LastName>
				<Affiliation>Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng Third People&#039;s Hospital, Yancheng, Jiangsu 224000, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Hongye</FirstName>
				<LastName>Li</LastName>
				<Affiliation>Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng Third People&#039;s Hospital, Yancheng, Jiangsu 224000, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Haiyan</FirstName>
				<LastName>Xu</LastName>
				<Affiliation>Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng Third People&#039;s Hospital, Yancheng, Jiangsu 224000, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Rujing</FirstName>
				<LastName>Chen</LastName>
				<Affiliation>Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng Third People&#039;s Hospital, Yancheng, Jiangsu 224000, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Juan</FirstName>
				<LastName>Lin</LastName>
				<Affiliation>Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng Third People&#039;s Hospital, Yancheng, Jiangsu 224000, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Juan</FirstName>
				<LastName>Wang</LastName>
				<Affiliation>Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng Third People&#039;s Hospital, Yancheng, Jiangsu 224000, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            		</AuthorList>
		<PublicationType>Journal Article</PublicationType>
		<History>
			<PubDate PubStatus="received">
				<Year>2023</Year>
				<Month>10</Month>
				<Day>03</Day>
			</PubDate>
		</History>
		<Abstract>Objective: To probe the impacts of whole-process health education based on self-management theory on self-efficacy as well as quality of life in lung cancer patients.
Methods: One hundred lung cancer patients undergoing chemotherapy in our hospital from January 2021 to December 2022 were selected and allotted into two groups on the basis of the time they came to the hospital. Patients in the CG received routine health education. Patients in the SG applied whole-process health education based on self-management theory. The psychological state, self-care ability, self-management efficacy, compliance, quality of life, along with nursing satisfaction in both groups was compared.
Results: Previous to education, no significance was seen in scores of SAS, SDS, ESCA, C-SUPPH as well as quality of life between both groups (P&gt;0.05). After education, SAS together with SDS scores in both groups were declined compared to before education (P&lt;0.05), and those in the SG were lower in contrast to the CG (P&lt;0.05). Each dimention of ESCA, C-SUPPH and quality of life scores in both groups was elevated compared to before education (P&lt;0.05), and those in the SG were higher relative to the CG (P&lt;0.05). The number of patients with on-time treatment, treatment compliance, functional training and timely review in the SG were elevated relative to the CG (P&lt;0.05). The nursing satisfaction in the SG was better in contrast to the CG (P&lt;0.05).
Conclusion: The whole-process health education based on self-management theory can effectively improve patients’ bad mentality, compliance, self-efficacy, quality of life along with nursing satisfaction.</Abstract>
		<ObjectList>
            		</ObjectList>
	</Article>
		<Article>
		<Journal>
			<PublisherName>OICC PRESS</PublisherName>
			<JournalTitle>Bioinformatic analysis of differential expression of pyroptosis related genes in cerebral infarction</JournalTitle>
			<Issn></Issn>
			<Volume>Volume 13 (2022) IJIC</Volume>
			<Issue>Issue 1, March 2022</Issue>
			<PubDate PubStatus="epublish">
                <Year>2023</Year>
                <Month>10</Month>
                <Day>03</Day>
			</PubDate>
		</Journal>
		<ArticleTitle>Bioinformatic analysis of differential expression of pyroptosis related genes in cerebral infarction</ArticleTitle>
		<VernacularTitle></VernacularTitle>
		<FirstPage></FirstPage>
		<LastPage></LastPage>
		<ELocationID EIdType="doi">10.47176/IJIC.13.1.7</ELocationID>
		<Language>EN</Language>
		<AuthorList>
            			<Author>
                				<FirstName>Renzhi</FirstName>
				<LastName>Deng</LastName>
				<Affiliation>Department of Neurosurgery, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530000, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Jianying</FirstName>
				<LastName>Chen</LastName>
				<Affiliation>Department of Operation Room, The Second Nanning People&#039;s Hospital, Nanning, Guangxi 530000, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Xianhui</FirstName>
				<LastName>Pang</LastName>
				<Affiliation>Department of Neurosurgery, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530000, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Xu</FirstName>
				<LastName>Han</LastName>
				<Affiliation>Department of Neurosurgery, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530000, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Chunhai</FirstName>
				<LastName>Tang</LastName>
				<Affiliation>Department of Neurosurgery, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530000, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            		</AuthorList>
		<PublicationType>Journal Article</PublicationType>
		<History>
			<PubDate PubStatus="received">
				<Year>2023</Year>
				<Month>10</Month>
				<Day>03</Day>
			</PubDate>
		</History>
		<Abstract>Cerebral infarction is also called ischemic stroke, is caused by various causes of local brain tissue regional blood supply disorders, resulting in brain tissue ischemic hypoxic lesion necrosis. Pyroptosis has been demonstrated in recent years to be an inflammatory form of programmed cell death. However, the expression of pyroptosis-related genes in cerebral infarction is obscure. The GSE122709 dataset was separated into cerebral infarction group and healthy control group. Eleven differentially expressed pyroptosis-related genes were selected, including CASP3, CASP9, ELANE, GPX4, GSDMD, NLRC4, PYCARD and SCAF11 were significantly down-regulated while GSDMB, NLRP1 and TIRAP were significantly up-regulated in cerebral infarction group in comparison with the controls. Go enrichment and KEGG pathway analysis have been performed for the differentially expressed pyroptosis-related genes. The outcomes showed that, in terms of biological process, most of pyroptosis-related DEGs were involved in the regulation of metabolic process, cellular compaonent organization, multicellular organismal process, response to stimulus, multi-organism process and biological regulation. In terms of cellular component, most of pyroptosis-related DEGs were implicated in cytosol and protein-containing complex, nucleus and membrane-enclosed lumen. In terms of molecular function, most of pyroptosis-related DEGs were involved in protein binding, and ion binding. Furthermore, we analyzed the enriched pathway of 11 pyroptosis-related DEGs, and displayed the mostly enriched pathway of pyroptosis-related DEGs (CASP9, CASP3, NLRC4 and PYCARD), which included mitochondrial apoptotic pathway. In conclusion, pyroptosis related genes may function as biomarkers for the cerebral infarction patients and may also serve as potential therapeutic targets.</Abstract>
		<ObjectList>
            		</ObjectList>
	</Article>
		<Article>
		<Journal>
			<PublisherName>OICC PRESS</PublisherName>
			<JournalTitle>Impacts of dexmedetomidine in association with sevoflurane anesthesia on postoperative pain along with recovery in elderly patients with lower limb fractures</JournalTitle>
			<Issn></Issn>
			<Volume>Volume 13 (2022) IJIC</Volume>
			<Issue>Issue 1, March 2022</Issue>
			<PubDate PubStatus="epublish">
                <Year>2023</Year>
                <Month>10</Month>
                <Day>03</Day>
			</PubDate>
		</Journal>
		<ArticleTitle>Impacts of dexmedetomidine in association with sevoflurane anesthesia on postoperative pain along with recovery in elderly patients with lower limb fractures</ArticleTitle>
		<VernacularTitle></VernacularTitle>
		<FirstPage></FirstPage>
		<LastPage></LastPage>
		<ELocationID EIdType="doi">10.47176/IJIC.13.1.8</ELocationID>
		<Language>EN</Language>
		<AuthorList>
            			<Author>
                				<FirstName>Pei</FirstName>
				<LastName>Li</LastName>
				<Affiliation>Department of Anesthesiology Institute, Xiaoshan Traditional Chinese Medical Hospital, Hangzhou, 311201, Zhejiang, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Lixiang</FirstName>
				<LastName>Cao</LastName>
				<Affiliation>Department of Anesthesiology Institute, Xiaoshan Traditional Chinese Medical Hospital, Hangzhou, 311201, Zhejiang, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Li</FirstName>
				<LastName>Lv</LastName>
				<Affiliation>Department of Anesthesiology Institute, Xiaoshan Traditional Chinese Medical Hospital, Hangzhou, 311201, Zhejiang, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            		</AuthorList>
		<PublicationType>Journal Article</PublicationType>
		<History>
			<PubDate PubStatus="received">
				<Year>2023</Year>
				<Month>10</Month>
				<Day>03</Day>
			</PubDate>
		</History>
		<Abstract>This study aimed to probe the influence of dexmedetomidine in association with sevoflurane anesthesia on postoperative pain and recovery in elderly lower limb fractures patients. A total of 120 elderly lower limb fractures patients received surgery were chosen and separated into control group (CG) and observation group (OG) following the random stratified sampling method. The OG adopted dexmedetomidine in association with sevoflurane anesthesia, and the CG adopted dexmedetomidine in association with propofol anesthesia. The hemodynamics indicators, sedation and analgesia, stress response, T helper cytokines levels, MMSE scores, along with incidence of adverse reactions in both groups were compared.
HR and MAP were increased and then decreased at T1-T4 in CG (P&lt;0.05). VAS and Ramsay sedation scores at 6, 12 and 24h followed by operation in both groups continued to decrease (P&lt;0.05). 24h after surgery, NE, E and Cor levels were elevated, and those in the OG were lessened (P&lt;0.05). IFN-γ and TNF-α levels were declined, and those in the OG were elevated (P&lt;0.05). The MMSE scores at 6, 12 and 24h followed by operation in CG were declined (P&lt;0.05). There were obvious differences of MMSE scores between immediately after operation and 6, 12h followed by operation (P&lt;0.05). The MMSE scores at 6, 12 and 24h followed by operation in the OG were elevated (P&lt;0.05).
Dexmedetomidine combined with sevoflurane anesthesia is beneficial to protect the postoperative cognitive function of elderly lower limb fractures patients undergo surgical treatment and reduce postoperative pain to a greater extent.</Abstract>
		<ObjectList>
            		</ObjectList>
	</Article>
		<Article>
		<Journal>
			<PublisherName>OICC PRESS</PublisherName>
			<JournalTitle>Establishment and value of epidemic management system in general hospitals</JournalTitle>
			<Issn></Issn>
			<Volume>Volume 13 (2022) IJIC</Volume>
			<Issue>Issue 1, March 2022</Issue>
			<PubDate PubStatus="epublish">
                <Year>2023</Year>
                <Month>10</Month>
                <Day>03</Day>
			</PubDate>
		</Journal>
		<ArticleTitle>Establishment and value of epidemic management system in general hospitals</ArticleTitle>
		<VernacularTitle></VernacularTitle>
		<FirstPage></FirstPage>
		<LastPage></LastPage>
		<ELocationID EIdType="doi">10.47176/IJIC.13.1.9</ELocationID>
		<Language>EN</Language>
		<AuthorList>
            			<Author>
                				<FirstName>Li</FirstName>
				<LastName>Wang</LastName>
				<Affiliation>Department of General Affairs Office, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Xiang</FirstName>
				<LastName>Li</LastName>
				<Affiliation>Department of Safety Supervision and Quality, Nanjing Huaqun Energy Group Co., Ltd., Nanjing, Jiangsu 210029, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Le</FirstName>
				<LastName>Luo</LastName>
				<Affiliation>Department of General Affairs Office, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Gang</FirstName>
				<LastName>Cao</LastName>
				<Affiliation>Department of R&amp;D, Nanjing Suyi Indsustry Co., Ltd., Nanjing, Jiangsu 210029, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            			<Author>
                				<FirstName>Chenglin</FirstName>
				<LastName>He</LastName>
				<Affiliation>Department of Union, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China</Affiliation>
				<Identifier Source="ORCID"></Identifier>
			</Author>
            		</AuthorList>
		<PublicationType>Journal Article</PublicationType>
		<History>
			<PubDate PubStatus="received">
				<Year>2023</Year>
				<Month>10</Month>
				<Day>03</Day>
			</PubDate>
		</History>
		<Abstract>The aim of this special was to explore the establishment of epidemic management system and the effect of epidemic prevention and control in general hospitals.The epidemiological data of emergency, outpatient, inpatient and hospital staff were selected as the study subjects. These data were divided into control group (n=7895) and observation group (n=4171) according to the establishment time of epidemic management system in our hospital, and data in the two groups were compared and analyzed. A group of 20 experts of epidemic management and prevention in our hospital were selected to evaluate the epidemic management system of our hospital.
The epidemic management ability and self-efficacy of medical workers after the system implementation were significantly improved (P&lt;0.05). Moreover, the qualified rate of epidemic report after system implementation was significantly elevated (P&lt;0.05), and the rate of missed reports and false reports were significantly reduced than those before system implementation (P&lt;0.05). The lost to follow-up rate of epidemiological survey quality report was significantly lower, while the completion, accuracy and patient satisfaction rates were significantly higher of the observation group than those of the control group. The epidemic management capability of our hospital was significantly improved after the establishment of a comprehensive epidemic management system. The risk of nosocomial infection was reduced and patient satisfaction was significantly improved by receiving epidemic patients in the emergency and outpatient clinics, which provide encouraging evidence of the potential effectiveness of the epidemic management system in general hospital.</Abstract>
		<ObjectList>
            		</ObjectList>
	</Article>
	</ArticleSet>
